Bad Homburg, Germany and Boulder, Colorado (USA).
Creathor has invested into Sinopsys Surgical, a clinical stage medical device company in Boulder, Colorado. Sinopsys has developed a stent device called the Sinopsys Lacrimal Stent. The lead indication for the stent is chronic rhinosinusitis with additional use in epiphora and potential in allergic rhinitis.
Participants in this Series C round beside Creathor are strategic, institutional and private investors. All of the company’s existing investors took part in the financing. “The company is very grateful for the strong support from both its existing and new investors.”, comments Harry Ross, CEO of Sinopsys, “We are eager to begin our next phase of U.S. trials in an exciting range of applications.” he adds.
“The Sinopsys Lacrimal Stent has the potential to help millions of patients suffering from chronic rhinosinusitis, an indication with high medical need and limited therapeutic options”, says Christian Leikert, Investment Manager at Creathor “We are looking forward to working with Sinopsys in this exiting environment.”
The funds will be used to further develop the Sinopsys Lacrimal Stent in clinical trials and to prepare the regulatory filings as well as the market launch of the device.